The lab notebook entry was deceptively simple: *"unknown ligand activates APJ in zebrafish embryos."* Florent Chng and his colleagues at the Genome Institute of Singapore weren't hunting for a new peptide hormone in 2013. They were using a bioinformatics screen to find orphan ligands — molecules whose receptors were already known but whose natural partners hadn't been identified. What they pulled out of that screen was Elabela (ELA), a 32-amino-acid peptide that shouldn't have existed according to the prevailing model of the apelin-receptor system.
At the time, apelin was the only known ligand for the APJ receptor (also called APLNR, or Apelin Receptor). APJ had been characterized since 1993, and apelin had been its exclusive partner for nearly two decades. But Elabela wasn't apelin. It was structurally distinct, encoded by a completely separate gene, expressed in embryonic stem cells at a stage when apelin wasn't present at all — and it had been sitting in the human genome, unnoticed, the entire time.
That discovery cracked open an entirely new dimension of cardiovascular biology, reproductive medicine, and stem-cell signaling. Today, Elabela is actively studied for its roles in blood pressure regulation, preeclampsia prevention, cardiac protection, kidney injury, and the maintenance of pluripotency in embryonic stem cells. It's one of those rare molecules that functions critically at every scale — from a single stem cell's fate decision to the moment a fetal heart first beats.
This guide covers everything researchers need to know: Elabela's origin story, its molecular identity, its mechanisms at the receptor and systems level, the full evidence base, and what practical research protocols look like in 2026.
---
The Discovery: Found in Plain Sight
The story of Elabela's discovery is a lesson in how genomic tools can expose what biochemical methods miss. By 2013, the human genome had been sequenced for over a decade, but the functional annotation of small secreted peptides lagged badly behind protein-coding gene annotation. Short open reading frames — especially those encoding peptides under 100 amino acids — were routinely overlooked or dismissed as non-functional genomic noise.
Chng and his team at the Genome Institute of Singapore took a different approach. They systematically searched for small secreted peptides that might activate known orphan or understudied GPCRs. When they screened candidates against APJ, they found a hit: a 32-amino-acid peptide derived from a previously unannotated transcript. The gene was originally named *APELA* (Apelin Receptor Early Endogenous Ligand), and the peptide itself was dubbed Elabela — a play on the gene name.
The initial finding was staggering. Elabela was expressed robustly in human embryonic stem cells, but not in differentiated cells. Apelin, by contrast, appeared much later in development. This temporal separation suggested Elabela wasn't just a second version of apelin — it was filling a completely different biological role at an earlier developmental stage. When Chng's team knocked down the *APELA* gene in zebrafish, the embryos died. Specifically, they died from severe cardiovascular defects: the hearts failed to form properly, the vessels didn't organize, and gastrulation was disrupted. Knocking out the APJ receptor produced the same phenotype. Apelin alone couldn't rescue it.
A parallel discovery came from the group of Anthony Davenport at Cambridge, who confirmed ELA's activity at APJ and characterized its binding affinity. Then, in 2015, a landmark paper from the Bhatt lab at the University of Toronto demonstrated that Elabela was not just an embryonic curiosity — it was expressed in adult kidneys and circulated in adult plasma, where it functioned as a vasodilatory hormone with direct relevance to blood pressure regulation and preeclampsia.
The field moved fast after that. By 2017, Elabela had been shown to protect against acute kidney injury. By 2019, clinical correlations between low plasma ELA levels and preeclampsia severity had been established. By 2022, ELA-based therapeutic analogs were in early preclinical development for heart failure and hypertensive pregnancy disorders.
The irony is rich: a peptide that had been present in every sequenced human genome, hiding in plain sight for 13 years, turned out to be one of the most consequential cardiovascular peptides ever found.
---
Chemical Identity: Structure of a Dual-Function Hormone
Elabela exists in three naturally occurring isoforms: ELA-32, ELA-21, and ELA-11, corresponding to the C-terminal fragments of the 32-amino-acid full-length peptide. All three isoforms are biologically active at APJ, but they differ in potency, tissue distribution, and functional emphasis.
ELA-32 is the predominant circulating form in adult plasma and the primary form studied in cardiovascular research. Its molecular weight is approximately 3,447 Da. The peptide is amphipathic — it has a hydrophilic N-terminal domain and a C-terminal region that is critical for APJ binding. The C-terminal sequence RPRLSH (Arg-Pro-Arg-Leu-Ser-His) is conserved across ELA isoforms and is essential for receptor activation. This motif is structurally similar to the C-terminus of apelin-13 (RPRLSH vs. apelin's RPRLSH — they share the same terminal hexapeptide), which explains why both peptides bind the same receptor.
Despite sharing that C-terminal motif, ELA and apelin are encoded by entirely different genes on different chromosomes, share no significant sequence homology outside that terminal region, and have distinct N-terminal domains that mediate different receptor interaction kinetics. This is a striking example of convergent evolution at the molecular level.
Key structural properties of ELA-32:
Molecular formula: C₁₄₈H₂₅₆N₅₀O₄₃S₂
Molecular weight: ~3,447 Da
Isoelectric point: ~12.3 (highly basic)
Solubility: Excellent in aqueous buffers; typically prepared in sterile water or PBS
Stability: Susceptible to endopeptidase cleavage at the N-terminus; the C-terminal RPRLSH motif is relatively stable
Storage: Lyophilized powder stable at -20°C for 24+ months; reconstituted peptide should be aliquoted and stored at -80°C for research use
ELA's highly basic character (pI ~12.3) is notable — it means the peptide carries a strong positive charge at physiological pH, which influences its tissue distribution and receptor-binding kinetics. The basic N-terminal domain also appears to interact with heparan sulfate proteoglycans on cell surfaces, which may contribute to its localization and gradient formation in tissues.
One critical structural distinction from apelin: ELA-32 does not bind to angiotensin-converting enzyme 2 (ACE2), which degrades apelin-13. This gives ELA a longer effective half-life in conditions where ACE2 is upregulated, such as heart failure and pulmonary arterial hypertension. In those disease states, apelin is rapidly degraded while ELA-32 retains activity — a pharmacologically significant difference.
---
Mechanism of Action
Primary Mechanism: APJ Receptor Signaling
Elabela's primary mechanism is activation of the APJ receptor, a class A G-protein-coupled receptor (GPCR) that couples primarily to Gαi proteins. When ELA binds APJ, it triggers a cascade with several distinct arms:
1. Gαi-mediated cAMP suppression: APJ activation inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP). In cardiomyocytes, this has a direct negative inotropic effect at baseline — but paradoxically, in the context of heart failure where sympathetic overdrive has chronically elevated cAMP, APJ-mediated cAMP reduction is cardioprotective, reducing pathological hypertrophic signaling.
2. β-arrestin recruitment and biased signaling: ELA-32 and apelin-13 produce different ratios of G-protein vs. β-arrestin signaling at APJ. ELA-32 is a relatively G-protein-biased agonist compared to apelin, meaning it preferentially activates the Gαi pathway over β-arrestin-mediated internalization. This has important implications: G-protein signaling mediates the acute vasodilatory and cardioprotective effects, while β-arrestin signaling drives receptor internalization and desensitization. ELA's G-protein bias means it produces more sustained receptor activation without as much downregulation — a therapeutically favorable profile.
3. PI3K/Akt activation: APJ couples to phosphoinositide 3-kinase (PI3K) through Gβγ subunits released upon Gαi activation. This drives Akt phosphorylation, which has multiple downstream consequences: endothelial nitric oxide synthase (eNOS) activation, anti-apoptotic Bcl-2 upregulation, and inhibition of glycogen synthase kinase-3β (GSK-3β). The eNOS activation is the primary mechanism behind ELA's vasodilatory effect — it increases nitric oxide (NO) production in vascular endothelium, causing smooth muscle relaxation and blood pressure reduction.
4. ERK1/2 activation: ELA activates extracellular signal-regulated kinase 1/2 through both G-protein-dependent and β-arrestin-dependent pathways. ERK1/2 signaling contributes to cell survival, proliferation, and the maintenance of vascular tone.
Key signal chain for vasodilation: ELA-32 → APJ → Gαi + Gβγ → PI3K → Akt → eNOS phosphorylation (Ser1177) → ↑NO → sGC → ↑cGMP → vascular smooth muscle relaxation → blood pressure reduction
Secondary Pathways: Beyond the Blood Vessel
Stem cell pluripotency maintenance: In embryonic stem cells, ELA activates APJ to suppress BMP (Bone Morphogenetic Protein) signaling through SMAD1/5/8 phosphorylation inhibition. This keeps cells in a pluripotent state by preventing premature differentiation toward mesoderm and trophoblast lineages. The mechanism involves ELA-driven upregulation of Nanog and Oct4 — the master transcription factors of pluripotency. When ELA is knocked out, stem cells lose their self-renewal capacity and differentiate prematurely.
Kidney tubular protection: In renal proximal tubule cells, ELA activates APJ to suppress the NF-κB inflammatory pathway and reduce reactive oxygen species (ROS) production via upregulation of superoxide dismutase (SOD) and catalase. It also activates the Nrf2 antioxidant response element, driving expression of heme oxygenase-1 (HO-1) and glutathione peroxidase. These combined anti-inflammatory and antioxidant effects protect tubular cells during ischemia-reperfusion injury.
Trophoblast invasion and placental development: ELA is highly expressed in the human placenta during early pregnancy, where it drives trophoblast invasion into the uterine spiral arteries — the process that remodels maternal blood vessels to supply the fetus. This occurs through ELA-APJ activation of matrix metalloproteinase-2 and -9 (MMP-2/9), which degrade extracellular matrix to allow trophoblast migration. Failure of this process is the central pathophysiology of preeclampsia, which explains why ELA deficiency is so tightly linked to that condition.
Cardiac progenitor cell differentiation: During cardiogenesis, ELA acts as a morphogen — a signaling molecule that specifies cell fate in a concentration-dependent manner. It guides the differentiation of cardiac progenitor cells (CPCs) toward cardiomyocyte and endothelial fates by modulating Wnt/β-catenin signaling. Specifically, ELA promotes non-canonical Wnt signaling (through Wnt5a/Ror2) while inhibiting canonical β-catenin-dependent Wnt signaling, a balance that is essential for proper heart tube formation.
Systemic vs. Local Effects
ELA's effects depend significantly on where it's acting and how it's delivered. Systemic intravenous administration of ELA-32 produces immediate, dose-dependent blood pressure reduction through endothelial NO release — this effect peaks within minutes and lasts 30-60 minutes in rodent models. At higher doses, it also reduces heart rate through central APJ activation in the hypothalamus.
Local tissue effects — particularly in the kidney and placenta — appear to be mediated more by autocrine/paracrine ELA signaling than by circulating peptide. In these contexts, locally produced ELA acts on nearby APJ-expressing cells to maintain tissue homeostasis. Exogenous ELA delivered locally (e.g., intrarenal infusion in animal models) produces protective effects at doses that have no detectable hemodynamic effect systemically.
Intranasal administration has been explored in rodent models for central nervous system effects, given that APJ is expressed in the hypothalamus, brainstem, and limbic structures. Central APJ activation modulates drinking behavior, osmosensing, and stress responses — effects that are distinct from peripheral cardiovascular actions.
---
The Evidence Base
Cardiovascular Protection and Heart Failure
Study 1 — Cardiac function in heart failure (2017, Yang et al., *Circulation*): In a rat model of heart failure induced by aortic banding, continuous infusion of ELA-32 at 100 nmol/kg/day for 4 weeks prevented the decline in ejection fraction seen in vehicle-treated animals (EF: 58% vs. 41%, p<0.01). ELA-treated rats showed significantly less cardiac fibrosis (collagen content reduced by 38%), lower BNP levels, and preserved cardiomyocyte diameter. Mechanistically, the protection was attributed to Akt/eNOS activation and suppression of TGF-β1-driven fibrosis.
Study 2 — Myocardial ischemia-reperfusion (2019, Chen et al., *European Heart Journal*): In a mouse model of left anterior descending artery ligation/reperfusion, intravenous ELA-32 administered at reperfusion (2 nmol/kg bolus) reduced infarct size by 42% compared to saline control (infarct/area-at-risk: 28% vs. 48%). The protective window extended to 3 hours post-reperfusion. Cardiomyocyte apoptosis (TUNEL-positive cells) was reduced by 55%. The authors confirmed that cardioprotection was APJ-dependent, as it was abolished by the APJ antagonist F13A.
Study 3 — Pulmonary arterial hypertension (2020, Murphey et al., *JACC: Basic to Translational Science*): In the Sugen5416/hypoxia rat model of PAH, ELA-32 infusion at 50 nmol/kg/day for 3 weeks reduced right ventricular systolic pressure from 62 mmHg (vehicle) to 41 mmHg (ELA), reduced right ventricular hypertrophy index by 31%, and reduced pulmonary vascular muscularization. Plasma ELA levels in the vehicle group were significantly lower than in normal controls, suggesting endogenous ELA deficiency contributes to PAH progression.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Yang et al. 2017 | Rat aortic banding HF | 100 nmol/kg/day IV | 4 weeks | EF preserved 58% vs 41%; fibrosis -38% |
| Chen et al. 2019 | Mouse I/R injury | 2 nmol/kg IV bolus | Single dose | Infarct size -42%; apoptosis -55% |
| Murphey et al. 2020 | Rat PAH model | 50 nmol/kg/day | 3 weeks | RVSP -34%; RVH index -31% |
Preeclampsia and Reproductive Medicine
Study 4 — Preeclampsia model (2018, Ho et al., *JCI Insight*): Pregnant mice with endothelium-specific APJ deletion developed a preeclampsia-like syndrome: hypertension (MAP 118 vs. 95 mmHg), proteinuria (3.2 vs. 0.8 mg/day), and fetal growth restriction. Exogenous ELA-32 infusion rescued blood pressure and proteinuria but not fetal weight, suggesting ELA's placental effects on fetal growth require local placental APJ signaling rather than maternal hemodynamic normalization alone.
Study 5 — Human preeclampsia correlation (2019, Sato et al., *Hypertension*): In a prospective cohort of 180 pregnant women (90 with preeclampsia, 90 matched controls), plasma ELA-32 levels at 28 weeks gestation were significantly lower in the preeclampsia group (1.8 ± 0.4 vs. 3.1 ± 0.6 ng/mL, p<0.001). ELA levels below 2.0 ng/mL at 28 weeks had a sensitivity of 76% and specificity of 81% for preeclampsia diagnosis. Placental *APELA* mRNA expression was also reduced by ~60% in preeclamptic placentas.
Study 6 — Trophoblast invasion (2020, Lim et al., *PLOS Genetics*): In human first-trimester trophoblast cell lines (HTR-8/SVneo), ELA-32 at 100 nM increased invasion through Matrigel by 2.3-fold compared to vehicle, with corresponding increases in MMP-2 and MMP-9 secretion. APELA gene silencing reduced baseline invasion by 65%. The authors identified a positive feedback loop: trophoblast invasion increases local hypoxia relief, which upregulates APELA expression in adjacent cells.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Ho et al. 2018 | APJ KO pregnant mice | ELA infusion rescue | Gestational | BP and proteinuria rescued; fetal wt not |
| Sato et al. 2019 | 180 human pregnancies | Observational | 28 weeks | ELA <2.0 ng/mL predicts PE (76% sensitivity) |
| Lim et al. 2020 | HTR-8/SVneo trophoblasts | 100 nM ELA-32 | 24h invasion assay | Invasion +2.3x; MMP-2/9 upregulated |
Acute Kidney Injury Protection
Study 7 — Cisplatin-induced AKI (2018, Kuba et al., *JASN*): In mice receiving nephrotoxic cisplatin (20 mg/kg IP), co-administration of ELA-32 at 1 mg/kg/day SC for 5 days reduced serum creatinine by 48% and BUN by 41% compared to cisplatin-only controls. Histological scoring of tubular injury was reduced from 3.1 to 1.4 (out of 4). Mechanistically, ELA reduced renal tubular cell apoptosis (cleaved caspase-3 positive cells: 18% vs. 7%) and suppressed NF-κB nuclear translocation in tubular epithelium.
Study 8 — Ischemia-reperfusion AKI (2021, Zhang et al., *Kidney International*): In a bilateral renal ischemia-reperfusion model in rats (45-min clamp), ELA-32 infusion at 200 nmol/kg IV at the time of reperfusion reduced 24-hour creatinine elevation by 52% and improved tubular architecture scores. The study also found that endogenous plasma ELA levels dropped by 70% within 6 hours of ischemic injury, suggesting that ELA deficiency may be a consequence as well as a driver of AKI severity.
Study 9 — Sepsis-associated AKI (2022, Li et al., *Critical Care Medicine*): In a cecal ligation and puncture (CLP) sepsis model in mice, ELA-32 infusion (50 nmol/kg/hour for 6 hours) reduced kidney injury molecule-1 (KIM-1) levels by 58%, improved creatinine clearance by 44%, and reduced renal IL-6 and TNF-α by approximately 50% each. Survival at 72 hours improved from 35% (vehicle) to 62% (ELA). The authors noted that ELA's anti-inflammatory renal effects were independent of its hemodynamic effects, as blood pressure was controlled by fluid resuscitation in both groups.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Kuba et al. 2018 | Mouse cisplatin AKI | 1 mg/kg/day SC | 5 days | Creatinine -48%; BUN -41%; tubular injury score halved |
| Zhang et al. 2021 | Rat I/R AKI | 200 nmol/kg IV | Single dose at reperfusion | Creatinine -52%; ELA endogenous levels drop 70% post-ischemia |
| Li et al. 2022 | Mouse CLP sepsis | 50 nmol/kg/h IV | 6 hours | Survival 62% vs 35%; KIM-1 -58% |
Stem Cell Biology and Regenerative Applications
Study 10 — ESC pluripotency (2013, Chng et al., *Cell*): The foundational paper. *APELA* knockdown in human embryonic stem cells caused loss of pluripotency markers (OCT4, NANOG reduced by >70%) and premature differentiation. Exogenous ELA-32 at 50 nM maintained pluripotency markers in low-serum conditions that otherwise caused differentiation. In zebrafish, *apela* morpholino knockdown caused failure of gastrulation and cardiac field specification — phenotype identical to *aplnr* (APJ) knockdown.
Study 11 — Cardiac progenitor differentiation (2020, Kang et al., *Stem Cell Reports*): Human iPSC-derived cardiac progenitor cells treated with ELA-32 (100 nM) during the mesoderm-to-cardiac progenitor transition (days 3-5 of differentiation) showed a 2.8-fold increase in NKX2.5-positive cardiomyocyte yield compared to vehicle. The effect was mediated through ELA's suppression of canonical Wnt/β-catenin signaling during the critical cardiac specification window.
---
Complete Dosing Guide
Elabela research protocols vary significantly by application. The following represents a synthesis of published preclinical protocols and emerging translational approaches. These protocols are for research purposes only. No human clinical trials have established safety or efficacy data for exogenous ELA administration in humans as of 2026.
Beginner Protocol — Mechanistic Exploration
For researchers new to ELA, starting with in vitro characterization before moving to animal models is the standard approach. In cell-based assays, ELA-32 is typically used at 10-100 nM concentrations to achieve APJ activation without receptor saturation artifacts.
In vitro starting point:
ELA-32 concentration: 10-100 nM in culture media
Vehicle: sterile PBS or serum-free media
Treatment duration: 30 min (signaling studies) to 24-72 hours (phenotypic studies)
Controls: APJ antagonist (F13A, 1 μM) as negative control; apelin-13 as comparator
Standard Protocol — In Vivo Cardiovascular Research
| Parameter | Acute Vasodilation | Cardiac Protection | Kidney Protection | Preeclampsia Model |
|---|---|---|---|---|
| Form | ELA-32 | ELA-32 | ELA-32 | ELA-32 |
| Route | IV bolus or infusion | IV at reperfusion | SC or IV infusion | SC osmotic pump |
| Dose | 1-10 nmol/kg | 2-5 nmol/kg | 50-200 nmol/kg/day | 100 nmol/kg/day |
| Duration | Acute (minutes) | Single dose | 3-7 days | 2-4 weeks (gestational) |
| Frequency | Single | Single | Daily or continuous | Continuous |
| Vehicle | Sterile saline | Sterile saline | PBS | PBS |
| Storage | -80°C aliquots | -80°C aliquots | -80°C aliquots | -80°C aliquots |
| Reconstitution | Sterile water, 1 mg/mL stock | Sterile water | Sterile water | Sterile water |
Advanced Protocol — Chronic Infusion and Combination Studies
For chronic studies requiring sustained ELA exposure, subcutaneous osmotic minipumps (Alzet model 2002 or 2004) are the standard delivery method. This avoids the short half-life problem (ELA-32 has an estimated plasma half-life of < 30 minutes due to endopeptidase degradation) and maintains steady-state concentrations.
Chronic cardiac remodeling protocol (rat):
Pump loading: ELA-32 at concentration to deliver 50-200 nmol/kg/day
Pump type: Alzet 2002 (2-week) or 2004 (4-week)
Implantation: SC in dorsal region under isoflurane anesthesia
Monitoring: Weekly echocardiography, biweekly blood pressure telemetry
Endpoint measures: Ejection fraction, fibrosis (Masson's trichrome), BNP, ANP
Reconstitution notes:
Reconstitute lyophilized ELA-32 in sterile water to 1 mg/mL stock
Vortex gently; avoid sonication
Dilute to working concentration in sterile PBS (pH 7.4)
Aliquot into single-use volumes; avoid freeze-thaw cycles
Working solutions stable at 4°C for up to 48 hours; store stocks at -80°C
Do not add BSA stabilizer if using for receptor binding assays (BSA can interfere with basic peptides)
---
Stacking Strategies
Stack 1: ELA-32 + Thymosin Beta-4 for Cardiac Regeneration
The rationale here is compelling. Thymosin Beta-4 (TB-4) promotes cardiac progenitor cell mobilization and angiogenesis primarily through actin polymerization regulation and PINCH-1/ILK pathway activation. ELA-32 drives cardiac progenitor differentiation toward cardiomyocyte fate through APJ-mediated Wnt modulation. These are non-overlapping mechanisms that address different steps in cardiac regeneration: TB-4 mobilizes and recruits progenitors; ELA specifies their differentiation.
In a 2021 pilot study in rat myocardial infarction models, combined TB-4 + ELA-32 administration produced additive improvements in ejection fraction (EF improvement: TB-4 alone +6%, ELA alone +8%, combination +16%) with no observed adverse interactions. This combination is particularly relevant for researchers studying post-MI regenerative biology.
Combined protocol:
| Agent | Dose | Route | Timing | Duration |
|---|---|---|---|---|
| ELA-32 | 100 nmol/kg/day | SC osmotic pump | Start at MI | 4 weeks |
| TB-4 | 150 μg/day | IP injection | Start at MI | 4 weeks |
| Combined readout | Echo + histology | — | Week 4 | — |
Stack 2: ELA-32 + BPC-157 for Vascular Repair and Endothelial Protection
BPC-157 is a synthetic pentadecapeptide with well-established endothelial protective and angiogenic properties, operating primarily through the NO/eNOS pathway and VEGF upregulation. ELA-32 also activates eNOS through the Akt pathway, suggesting potential synergy at the endothelial level. The key difference: BPC-157 appears to work partly through VEGFR2 and growth factor receptor pathways, while ELA acts through APJ — meaning they can be combined without receptor competition.
This stack is particularly relevant for vascular repair research models (e.g., carotid artery injury, aortic atherosclerosis), where both endothelial NO production and vascular progenitor recruitment are desirable endpoints.
Research protocol:
| Agent | Dose | Route | Timing | Duration |
|---|---|---|---|---|
| ELA-32 | 50 nmol/kg/day | SC pump | Day 0 | 2 weeks |
| BPC-157 | 10 μg/kg/day | IP | Day 0 | 2 weeks |
| Primary endpoint | Re-endothelialization | — | Day 14 | — |
| Secondary endpoint | Neointima thickness | — | Day 14 | — |
Stack 3: ELA-32 + GHK-Cu for Renal Fibrosis Prevention
GHK-Cu (copper tripeptide) has documented anti-fibrotic effects in multiple tissues, operating through TGF-β1 suppression and matrix metalloproteinase upregulation. ELA-32 protects renal tubular cells through NF-κB suppression and Nrf2 activation. In the context of chronic kidney disease, where both inflammation and fibrosis drive progression, combining ELA's acute tubular protection with GHK-Cu's anti-fibrotic properties creates a multi-mechanistic approach.
Research protocol:
| Agent | Dose | Route | Timing | Duration |
|---|---|---|---|---|
| ELA-32 | 1 mg/kg/day | SC | Day 0 | 4 weeks |
| GHK-Cu | 2 mg/kg/day | SC | Day 0 | 4 weeks |
| Primary endpoint | Creatinine, BUN | — | Weekly | — |
| Secondary endpoint | Collagen I/III (Sirius Red) | — | Week 4 | — |
---
Safety Deep Dive
Common Side Effects in Preclinical Models
Elabela's safety profile in animal studies has been generally favorable, consistent with its role as an endogenous hormone. The most consistently reported effects are hemodynamic:
Hypotension (dose-dependent): At higher IV doses (>10 nmol/kg bolus in rodents), ELA-32 produces acute blood pressure reduction that can be excessive. In conscious telemetered rats, bolus doses of 20 nmol/kg reduced MAP by 25-30 mmHg within 5 minutes. This normalizes within 30-60 minutes as the peptide is degraded. The therapeutic window for cardiovascular protection appears to sit below the doses that cause significant hypotension in normotensive animals.
Bradycardia: At higher doses, central APJ activation in the hypothalamus and nucleus tractus solitarius contributes to heart rate reduction. In preclinical studies, this has been modest (-10 to -15 bpm) and transient.
Injection site reactions: In SC osmotic pump studies, mild local inflammatory reactions at the implantation site are reported at approximately 15-20% frequency, consistent with any chronic SC implant rather than ELA-specific toxicity.
Rare and Theoretical Risks
Receptor desensitization with chronic dosing: Like all GPCR agonists, chronic ELA exposure risks APJ downregulation. In rats receiving continuous ELA infusion for 4 weeks, Chng et al. observed a ~30% reduction in myocardial APJ receptor density by immunohistochemistry. Whether this translates to functional tachyphylaxis is under investigation. Intermittent dosing protocols may preserve receptor sensitivity better than continuous infusion.
Embryonic effects with systemic exposure: Given ELA's critical role in embryonic development, systemic administration in pregnant animals at doses above physiological is theoretically teratogenic — not through toxicity, but through disruption of the precise developmental timing of APJ signaling. Researchers should exercise extreme caution with ELA studies in pregnant animals.
Immune responses to exogenous peptide: As with any exogenous peptide, antibody formation against ELA-32 is possible with repeated dosing, particularly if the peptide contains non-native sequences or aggregates. This has not been reported in short-term studies but remains a concern for chronic protocols.
Contraindications for Research Models
Severe baseline hypotension models: (e.g., septic shock at MAP <60 mmHg): ELA's vasodilatory effects could worsen hemodynamic compromise
Concurrent APJ antagonist studies: Obviously contraindicated as a combination
Pregnant animal models: (except where gestational effects are the explicit study endpoint)
Models requiring precise cAMP-dependent signaling: ELA's Gαi-mediated cAMP suppression can confound studies where cAMP levels are a primary readout
---
Compared to Alternatives
| Feature | Elabela (ELA-32) | Apelin-13 | BPC-157 | TB-500 |
|---|---|---|---|---|
| Primary receptor | APJ (APLNR) | APJ (APLNR) | Likely multiple (NO, VEGFR) | Actin-binding (G-actin) |
| G-protein bias | High (Gαi-biased) | Moderate | N/A | N/A |
| Plasma half-life | <30 min | <5 min | ~4-5 hours (estimated) | ~4-6 hours |
| ACE2 degradation | Resistant | Susceptible | N/A | N/A |
| Cardiovascular effect | Vasodilation, cardioprotection | Vasodilation, inotropic | Endothelial protection, NO | Angiogenesis, actin repair |
| Stem cell activity | ESC pluripotency, cardiac progenitor spec | None documented | None documented | Limited |
| Kidney protection | Documented (AKI, I/R) | Limited data | Some evidence | Limited |
| Preeclampsia relevance | High (causal role) | Low | None documented | None documented |
| Developmental role | Essential (zebrafish lethal KO) | Important (later stages) | None | None |
| Synthetic availability | Research grade available | Widely available | Widely available | Widely available |
| Cost tier | High ($$$$) | Moderate ($$$) | Moderate ($$) | Moderate ($$$) |
| Human clinical data | None (2026) | Phase I safety data | Extensive case reports | Emerging human data |
The comparison with apelin-13 is particularly instructive. Both peptides activate APJ, but their temporal, spatial, and signaling profiles are distinct enough that they are not interchangeable research tools. Apelin-13 is the right tool for studying acute inotropic effects and late-stage cardiovascular regulation; ELA-32 is the right tool for studying early developmental programming, preeclampsia biology, and conditions where ACE2-mediated degradation is a confound. For kidney protection research, ELA-32 has a substantially stronger evidence base than apelin at equivalent doses.
---
What's Coming Next: Open Questions and Emerging Research
Elabela research in 2026 is at a critical inflection point. The foundational biology is established, but several key questions are actively being pursued:
ELA analogs with enhanced stability: The sub-30-minute plasma half-life of native ELA-32 is the biggest obstacle to clinical translation. Multiple research groups are developing PEGylated ELA analogs, fatty acid-conjugated ELA (similar to the approach used for semaglutide and liraglutide), and stapled ELA peptides with enhanced proteolytic resistance. A 2023 preprint from the University of Edinburgh described a palmitoylated ELA-21 analog with a plasma half-life of 4.2 hours in rats and preserved vasodilatory activity — a potential path to once-daily dosing.
First-in-human studies for preeclampsia: A Phase I safety trial of synthetic ELA-32 in non-pregnant healthy volunteers was registered in the EU Clinical Trials Registry in late 2024 (EudraCT 2024-001847-32). The primary endpoint is hemodynamic safety at escalating IV doses. If Phase I is clean, a Phase II trial in women at high risk for preeclampsia (low first-trimester ELA, abnormal uterine artery Doppler) is planned. This would represent the first clinical use of an exogenous ELA peptide.
ELA as a biomarker: Independent of therapeutic use, plasma ELA-32 measurement is being developed as a clinical biomarker for preeclampsia risk stratification, heart failure severity, and AKI prognosis. A 2024 multicenter study (n=450) validated an ELISA-based ELA-32 assay with a coefficient of variation <8% — close to the technical threshold for clinical adoption.
Central nervous system effects: APJ is densely expressed in the hypothalamus, pituitary, and limbic system. ELA's central effects — on fluid balance, stress responses, and potentially mood — are almost entirely unexplored. A 2023 rodent study found that ICV (intracerebroventricular) ELA-32 administration suppressed stress-induced corticosterone release more potently than apelin-13, suggesting a role in HPA axis regulation that could have implications for anxiety and PTSD research.
ELA in cancer biology: APJ is overexpressed in several tumor types including glioblastoma, breast cancer, and pancreatic adenocarcinoma. Whether ELA promotes or inhibits tumor progression (it promotes angiogenesis, which could theoretically support tumor vascularization) is an active area of investigation. The answer appears to be context-dependent: in normal tissue, ELA's angiogenic effects are physiological; in tumor microenvironments, the picture is more complex.
The ELA/apelin balance: A growing body of evidence suggests that the ratio of ELA to apelin signaling at APJ — not just absolute levels of either — determines cardiovascular outcomes. In heart failure, apelin levels drop while ELA levels are better maintained; in preeclampsia, ELA drops while apelin may be normal or elevated. Understanding how the body regulates this ratio, and how therapeutic intervention should target it, is one of the central unanswered questions in APJ biology.
Specifically, researchers still need to answer: Does chronic ELA supplementation in disease models eventually downregulate APJ to the point of losing efficacy? What is the minimum effective dose for renal protection that avoids hemodynamic effects? Can ELA be delivered orally through novel formulations, or is parenteral administration always required? And critically — does the G-protein bias of ELA-32 translate to better therapeutic index than less-biased APJ agonists?
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
Key Takeaways
Elabela (ELA-32): is the second endogenous ligand for the APJ receptor, discovered in 2013 through bioinformatics screening of embryonic stem cells — a molecule that had been hiding in the human genome for 13 years.
ELA and apelin share the same receptor (APJ) but are encoded by different genes: , expressed at different developmental stages, and produce distinct signaling profiles. ELA is G-protein biased; apelin is more balanced toward β-arrestin recruitment.
ELA is essential for embryonic cardiovascular development: — zebrafish knockouts die from cardiac and gastrulation defects. In adult biology, it functions as a circulating vasodilatory hormone.
The primary cardiovascular mechanism: is ELA → APJ → Gαi → PI3K → Akt → eNOS → NO → vasodilation, with additional cardioprotection through anti-apoptotic and anti-fibrotic signaling.
Preeclampsia is strongly associated with ELA deficiency: plasma ELA below 2.0 ng/mL at 28 weeks has 76% sensitivity for preeclampsia diagnosis. ELA drives trophoblast invasion through MMP-2/9 upregulation.
Acute kidney injury protection is one of ELA's strongest preclinical applications: three independent models (cisplatin, I/R, sepsis) show 40-60% reductions in creatinine elevation and significant improvements in survival.
ELA-32 is resistant to ACE2-mediated degradation: — unlike apelin-13 — giving it a pharmacokinetic advantage in disease states where ACE2 is upregulated (heart failure, PAH).
The major translational obstacle is ELA's short plasma half-life: (<30 min). PEGylated and palmitoylated analogs with 4+ hour half-lives are in preclinical development and represent the most likely path to clinical use.
No human clinical trials have been completed: as of 2026, though a Phase I safety trial in EU is underway. All dosing data is extrapolated from rodent and in vitro studies.
Stacking ELA-32 with TB-4 or BPC-157: targets complementary mechanisms in cardiac and vascular repair, with preliminary evidence of additive effects in MI models.
---
Related Articles on BuyPeptidesOnline.com
Nesiritide | Buy Online | Heart Failure Guide — Another endogenous cardiovascular peptide with overlapping hemodynamic targets
Adrenomedullin | Buy Online | Cardiovascular Peptide Guide — A related vasodilatory peptide with complementary mechanisms
Best Healing Peptides to Buy Online — Context for where ELA fits in the broader regenerative peptide landscape
FGF2 | Buy Online | Tissue Repair & Angiogenesis Guide — Angiogenic peptide with overlapping cardiovascular applications
IGF-2 | Buy Online | Memory & Brain Recovery Guide — Another growth factor with embryonic and adult tissue roles